Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3

Circulation Research

Volumn 96, Issue 8, 2005, Pages 913-920

  Tölle, Markus ^a   Levkau, Bodo ^b   Keul, Petra ^b   Brinkmann, Volker ^c   Giebing, Günter ^a   Schönfelder, Gilbert ^a   Schäfers, Michael ^d   Von Wnuck Lipinski, Karin ^b   Jankowski, Joachim ^a   Jankowski, Vera ^a   Chun, Jerold ^e   Zidek, Walter ^a   Van Der Giet, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

eNOS; FTY720; S1P receptor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FINGOLIMOD; IMMUNOMODULATING AGENT; LYSOPHOSPHOLIPID; N',N DIMETHYLSPHINGOSINE; NITRIC OXIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; SPHINGOSINE DERIVATIVE; SPHINGOSINE KINASE; UNCLASSIFIED DRUG;

AORTA; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN;

CELLS, CULTURED; ENZYME ACTIVATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROPYLENE GLYCOLS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LYSOSPHINGOLIPID; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPHINGOSINE; VASODILATION;

EID: 20944434884     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000164321.91452.00     Document Type: Article

References (47)

1. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. Fty720, a novel immunomodulator: efficacy and safety results from the first phase 2a study in de novo renal transplantation. Transplantation. 2004;77:1826-1833.
2. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator fty720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457.
3. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276:31780-31785.
4. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant fty720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003;554:189-193.
5. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thoraton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346-349.
6. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on sip receptor 1. Nature. 2004;427:355-360.
7. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407.
8. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids: receptor revelations. Science. 2001;294:1875-1878.
9. Pyne S, Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther. 2000;88:115-131.
10. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279:13839-13848.
11. English D, Welch Z, Kovala AT, Harvey K, Volpert OV, Brindley DN, Garcia JG. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J. 2000;14:2255-2265.
12. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, Tigyi G. International Union of Pharmacology, XXXIV: lysophospholipid receptor nomenclature. Pharmacol Rev. 2002;54:265-269.
13. Anliker B, Chun J. Lysophospholipid g protein-coupled receptors. J Biol Chem. 2004.
14. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321-354.
15. Igarashi J, Bernier SG, Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase: differential regulation of AKT and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem. 2001;276:12420-12426.
16. Tanimoto T, Jin ZG, Berk BC. Transactivation of vascular endothelial growth factor (VEGF) receptor flk-1/kdr is involved in sphingosine 1-phosphate-stimulated phosphorylation of AKT and endothelial nitric-oxide synthase (eNOS). J Biol Chem. 2002;277:42997-43001.
17. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, Walsh K, Hla T, Sessa WC. Sphingosine 1-phosphate activates akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276:19672-19677.
18. Joosten SA, van Kooten C, Sijpkens YW, de Fijter JW, Paul LC. The pathobiology of chronic allograft nephropathy: Immune-mediated damage and accelerated aging. Kidney Int. 2004;65:1556-1559.
19. Oflaz H, Turkmen A, Kazancioglu R, Kayacan SM, Bunyak B, Genchallac H, Erol B, Mercanoglu F, Umman S, Sever MS. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Transplant. 2003;17:212-216.
20. Levkau B, Scatena M, Giachelli CM, Ross R, Raines EW. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-κB loop. Nat Cell Biol. 1999;1:227-233.
21. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, Kingsbury MA, Zhang G, Brown JH, Chun J. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, 1p(b3)/edg-3. J Biol Chem. 2001;276:33697-33704.
22. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, Yang AH, Zhang G, Brown JH, Chun J. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors. s1p(2)/1p(b2)/edg-5 and s1p(3)/1p(b3)/edg-3. J Biol Chem. 2002;277:25152-25159.
23. Tepel M, Jankowski J, Ruess C, Steinmetz M, van der Giet M, Zidek W. Activation of Na+, H+ exchanger produces vasoconstriction of renal resistance vessels. Am J Hypertens. 1998;11:1214-1221.
24. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569-581.
25. van der Giet M, Schmidt S, Tolle M, Jankowski J, Schluter H, Zidek W, Tepel M. Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. Eur J Pharmacol. 2002;448:207-213.
26. Davda RK, Chandler LJ, Crews FT, Guzman NJ. Ethanol enhances the endothelial nitric oxide synthase response to agonists. Hypertension. 1993;21:939-943.
27. Sugimoto K, Fujii S, Takemasa T, Yamashita K. Detection of intracellular nitric oxide using a combination of aldehyde fixatives with 4,5- diaminofluorescein diacetate. Histochem Cell Biol. 2000;113:341-347.
28. Rathel TR, Leikert JJ, Vollmar AM, Dirsch VM. Application of 4,5-diaminofluorescein to reliably measure nitric oxide released from endothelial cells in vitro. Biol Proced Online. 2003;5:136-142.
29. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T. Phosphorylation and action of the immunomodulator fty720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem. 2003;278:47281-47290.
30. McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem. 2004;92:1075-1085.
31. Schaphorst KL, Chiang E, Jacobs KN, Zaiman A, Natarajan V, Wigley F, Garcia JG. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol. 2003;285:L258-L267.
32. Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol. 2003;284:H2045-H2052.
33. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, Waeber C. S1p3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol. 2003;469:125-134.
34. Banno Y, Takuwa Y, Yamada M, Takuwa N, Ohguchi K, Hara A, Nozawa Y. Involvement of phospholipase d in insulin-like growth factor-i-induced activation of extracellular signal-regulated kinase, but not phosphoinositide 3-kinase or AKT, in Chinese hamster ovary cells. Biochem J. 2003;369:363-368.
35. Kwon YG, Min JK, Kim KM, Lee DJ, Billiar TR, Kim YM. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J Biol Chem. 2001;276:10627-10633.
36. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by EDG-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689-701.
37. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301-312.
38. Boo YC, Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol Cell Physiol. 2003;285: C499-C508.
39. Butler J, Lana D, Round O, LaMontagne K. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Prostaglandins Other Lipid Mediat. 2004;73:29-45.
40. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res. 2002;91:151-157.
41. Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J, Schober O, Schäfers M. Hdl stimulates myocardial perfusion in vivo. Circulation. 2004;110:3355-3359.
42. Ohmori T, Yatomi Y, Osada M, Kazama F, Takafuta T, Ikeda H, Ozaki Y. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res. 2003;58:170-177.
43. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug fty720 by sphingosine kinases. J Biol Chem. 2003;278:47408-47415.
44. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, Hajdu R, Rosenbach M, Keohane CA, Mandala S, Spiegel S, Proia RL. Mice deficient in sphingosine kinase I are rendered lymphopenic by fty720. J Biol Chem. 2004;279:52487-52492.
45. Vos IH, Joles JA, Rabelink TJ. The role of nitric oxide in renal transplantation. Semin Nephrol. 2004;24:379-388.
46. Kiuchi M, Adachi K, Kohara T, Minoguchi M, Hanano T, Aoki Y, Mishina T, Arita M, Nakao N, Ohtsuki M, Hoshino Y, Teshima K, Chiba K, Sasaki S, Fujita T. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3- diols and 2-aminoethanols. J Med Chem. 2000;43:2946-2961.
47. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer H, Tian M, West S, White V, Xie J, Proia RL, Mandala S. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004;309:758-768.